1OO
THE TOP 1OO MEDTECH COMPANIES
ABBOTT Abbott Park, Ill. * Revenues from Abbott’s cardiovascular & neuromodulation segments.
2017 revenues:
$8,911,000,000
14
Fiscal year ending: December 31, 2017
KEY PERSONNEL:
MILES WHITE, chairman & CEO; HUBERY ALLEN, EVP, general counsel & secretary; BRAIN BLASER, EVP, diagnostic products; JOHN CAPEK, EVP, ventures; ROBERT FORD, EVP, medical devices; STEPHEN FUSSELL, EVP, human resources; ANDREW LANE, EVP, established pharmaceuticals; DANIEL SALVADORI, EVP, nutritional products; BRIAN YOUR, CFO & EVP, finance; ROGER BIRD, SVP, U.S. nutrition; SHARON BRACKEN, SVP, rapid diagnostics; CHUCK BRYNELSEN, SVP, Abbott Vascular; JAIME CONTRERAS, SVP, core laboratory diagnostics, commercial operations; ROBERT FUNCK, SVP, finance & controller; ELAINE LEAVENWORTH, SVP & chief marketing & external affairs officer; JOSEPH MANNING, SVP, international nutrition; CORLIS MURRAY, SVP, quality assurance, regulatory & engineering services; MICHAEL PETERSON, SVP, cardiac arrhythmias & heart failure; SEAN SHRIMPTON, SVP, established pharmaceuticals, emerging markets; JARED WATKIN, SVP, diabetes care; ALEJANDRO WELLISCH, SVP, established pharmaceuticals, Latin America
A
bbott followed the blockbuster, $25 billion St. Jude Medical buy with the $5 billion buyout of diagnostics company Alere in early October 2017, but otherwise trod quietly along the M&A trail. Although it took its first-generation Absorb bioresorbable stent off the market, Abbott won FDA approval for its Xience Sierra everolimus-eluting stent. And the bets it placed in the diabetes market proved out as that business grew at a healthy double-digit clip. M
46
Medical Design & Outsourcing
TOP 10 100 List_9-18_Vs4.indd 46
9 • 2018
www.medicaldesignandoutsourcing.com
9/18/18 2:46 PM